Anaptysbio (ANAB) Cash from Operations (2016 - 2026)
Anaptysbio's (ANAB) quarterly Cash from Operations came in at 25919000.0 in Q1 2026, down 142.23% YoY from 61370502.32 in Q1 2025, and down 126.45% on a QoQ basis from 97997000.0 in Q4 2025.
Anaptysbio (ANAB) Cash from Operations (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Cash from Operations data on file, last reported at 25919000.0 in Q1 2026.
- Quarterly Cash from Operations fell 142.23% year-over-year to 25919000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4478000.0 (up 104.12% YoY) and the FY2025 annual result came in at 19697000.0, up 114.55% from the prior year.
- Cash from Operations fell to 25919000.0 in Q1 2026, from 97997000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 97997000.0 in Q4 2025 to a low of 66672000.0 in Q4 2024.
- A 5-year average of 19761882.35 and a median of 24568000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 351.77% — and 2025, when it jumped 246.98%.
- Tracing ANAB's Cash from Operations over 5 years: stood at 10685000.0 in 2022, then slumped by 221.47% to 34349000.0 in 2023, then sank by 94.1% to 66672000.0 in 2024, then jumped by 246.98% to 97997000.0 in 2025, then tumbled by 126.45% to 25919000.0 in 2026.
- The last three Cash from Operations figures came in at 25919000.0 (Q1 2026), 97997000.0 (Q4 2025), and 27356000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -25.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.92 Mn |
| Mar 31, 2026 | -25.92 Mn |
| Dec 31, 2025 | 98.00 Mn |
| Dec 31, 2025 | 98.00 Mn |
| Sep 30, 2025 | -27.36 Mn |
| Sep 30, 2025 | -27.36 Mn |
| Jun 30, 2025 | -40.24 Mn |
| Jun 30, 2025 | -40.24 Mn |
| Mar 31, 2025 | -10.70 Mn |
| Mar 31, 2025 | -10.70 Mn |
| Dec 31, 2024 | -66.67 Mn |
| Dec 31, 2024 | -66.67 Mn |
| Sep 30, 2024 | -10.09 Mn |
| Sep 30, 2024 | -10.09 Mn |
| Jun 30, 2024 | -21.32 Mn |
| Jun 30, 2024 | -21.32 Mn |
| Mar 31, 2024 | -37.25 Mn |
| Mar 31, 2024 | -37.25 Mn |
| Dec 31, 2023 | -34.35 Mn |
| Dec 31, 2023 | -34.35 Mn |